Kilitch Drugs (India) Share Price

Kilitch Drugs

CMP as on 23-May-22 14:02

₹ 152.90
-4.35 -2.77%

Open

₹ 154.10

Turnover (lac)

₹ 5

Prev. Close

₹ 157.25

Day's Vol (shares)

₹ 3,513

Day's Range (₹)

₹ 150.35
₹ 157.80

CMP as on23-May-22 14:15

₹ 152.90
-4.1 -2.61%

Open

₹ 157.00

Turnover (lac)

₹ 1

Prev. Close

₹ 157.00

Day's Vol (shares)

₹ 436

Day's Range

₹ 152.90
₹ 157.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 07-Feb-2022 - -
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 inter alia to consider and approve We wish to inform you that the meeting of the Board of Directors of the Company will be held on Monday 14th February 2022 at the Corporate Office of the Company at Mumbai at 04.00 P.M.: ?To Consider and approve the Standalone and Consolidated Un-audited Financial Result of the Company for the quarter ended 31st December 2021; ?Any other matter with the permission of the Chair. Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2nd April 2019 issued by NSE the Trading Window has been closed with effect from Saturday 1st January 2022 and shall continue to remain closed till 48 hours after the announcement of the financial results on 14th February 2022. In continuation to our letter dated 7th February 2022, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 14th February, 2022, have - 1.Considered and approved the Un-audited financial results of the company for the quarter ended 31st December 2021; In this connection please find enclosed the copy of Un-audited Standalone & Consolidated financial Results of the Company for the quarter ended 31st December 2022 along with Limited Review Report by the Statutory Auditors of the Company as Annexure-I. The meeting commenced at 04: 00 P.M. and concluded at 07:00 P.M. The above is for information and dissemination to the public at large. (As per BSE Announcement Dated on 14/02/2022)
Board Meeting - 24-Jan-2022 - -
In furtherance to our letters dated December 15, 2021 and December 20, 2021 and in compliance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that Board Meeting of the Company held on January 24, 2022 has allotted 5,00,000 Warrants (1 Warrant convertible into 1 Equity Share of face value of Rs.10/- each) at a issue price of Rs. 177.15 (including premium of Rs. 167.15 per warrant) to the below mentioned persons/entities on preferential basis:- Sr. No. Name of allottees *Warrants (No) Category 1. Mr. Mukund Mehta 2,50,000 Promoter - Individual 2. Mr. Bhavin Mehta 2,50,000 Promoter - Individual Total 5,00,000 * 1 warrant will be converted into 1 equity share upon exercise of option by the warrant holder(s), within 18 months from the date of allotment of warrants. Consequently, the paid up equity share capital of the Company now stands increased from Rs. 15,58,23,190/- to Rs. 16,08,23,190/-.
Board Meeting - 15-Dec-2021 - -
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/12/2021 inter alia to consider and approve ?To issue Shares Warrants convertible into Equity Shares through Preferential Allotment to Promoters of the Company and pursuant to applicable provisions of the Companies Act 2013 along with applicable SEBI (LODR) Regulations 2015 SEBI (ICDR) Regulations 2018 as updated from time to time subject to the approval of members of the Company. ?To consider conducting EGM of the Company with respect to the above referred matter pursuant to applicable provisions of the Companies Act 2013 and approve the notice of the same. ?To appoint M/s Deep Shukla and Associates Practising Company Secretary as the Srutinizer of the Company for the process of E-voting. ?Any other matter with the permission of the Chair. 1.To issue equity shares and/or warrants convertible into equity shares on preferential basis at Rs. 177.15/- to the following Promoters to meet the long term working capital requirements, general corporate purpose and such other purpose as the Board may decide. Sr. No. Name Warrants (No) Category 1. Mr. Mukund Mehta 2,50,000 Promoter 2. Mr. Bhavin Mehta 2,50,000 Promoter The issue price has been determined in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. * Note: Every warrant is entitled to receive 1 equity share at the time of conversion. 2.Convening Extra-Ordinary General Meeting of the members of the Company on Wednesday, 19th January, 2022 at 01:00 P.M. through Video Conference (VC)/ Other Audio Visual Means (OAVM) (hereinafter referred to as electronic mode). (As Per BSE Announcement Dated on 20.12.2021)
Board Meeting - 02-Nov-2021 - -
Quarterly Results In continuation to our letter dated 2nd November 2021, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 12th November, 2021, have considered and approved the following- 1.The Un-audited financial results of the company for the quarter and half year ended 30th September 2021; (As per BSE Announcement Dated on 12/11/2021)
Board Meeting - 13-Oct-2021 - -
We wish to inform you that we have Considered and approved the appointment of Ms. Princy Asati (ACS 65847) as the Company Secretary and Compliance Officer of the Company in place of Ms. Garima Trivedi ( ACS 62636) w.e.f 13th October 2021. Approved the allotment of 20305 Stock Option to Employees of the Company and Subsidiary Companies pursuant to Kilitch Employee Stock Option Scheme 2007. Taken Note of the Grant of 105264 ESOPs on 13th October 2021 to 155 employees of the Company and Subsidiary Companies under the Kilitch Employee Stock Option Scheme 2020 (ESOP 2020) at an exercise price of 145/- per stock option vide a resolution passed by the Nomination and Remuneration Committee in its meeting held on 13th October 2021. Each of the ESOPs entitles the holder to apply for one Equity Share of the Company of INR 10/- each. The meeting commenced at 12:30 P.M. (IST) and concluded at 4:05 P.M.(IST)
Board Meeting - 05-Aug-2021 - -
Quarterly Results In continuation to our letter dated 5th August 2021 we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that the Board of Directors of the company at its meeting held today i.e. 13th August 2021 have considered and approved the following- 1.The Un-audited financial results of the company for the quarter ended 30th June 2021; In this connection please find enclosed the copy of Un-audited Standalone financial Results of the Company for the quarter ended 30th June 2021 along with Limited Review Report by the Statutory Auditors of the Company as Annexure-I. 2.The appointment of M/s Suryaprakash Maurya & Co (FRN: 147410W) as the Statutory Auditor of the Company to hold office from the conclusion of 29th AGM till the conclusion of 34th AGM. (As Per BSE Announcement Dated on 8/13/2021 5:09:34 AM)
Board Meeting - 15-Jun-2021 - -
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/06/2021 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Result of the Company for the quarter and financial year ended 31st March 2021; We enclosed herewith the audited standalone and consolidated financial results of the Company for the quarter and year ended 31st March, 2021, which have been approved and taken on record at the meeting of the Board of Directors of the Company held today, i.e. 22nd June, 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we would like to confirm that M/s. A.M. Ghelani & Co., Chartered Accountants (Firm Registration no. 103173W)), Statutory Auditors of the Company, have issued Audit Reports with unmodified opinion on the above financial results. The meeting of Board of Directors held today commenced at 4:00 PM and concluded at 5:35 PM. (AS Per BSE Announcement Dated on 22.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity